Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response
about
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsIncidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel diseaseTherapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndromeThe Intersection of TNF, IBD and the Microbiome.Integrin CD11b attenuates colitis by strengthening Src-Akt pathway to polarize anti-inflammatory IL-10 expression.Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease.Optimizing pharmacologic management of inflammatory bowel disease.Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review.Recombinant human MFG-E8 ameliorates colon damage in DSS- and TNBS-induced colitis in mice.Effectiveness and safety of infliximab in two cases of severe chondrocalcinosis: nine years of follow-up.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis.
P2860
Q26785537-C17B2E05-7253-4D30-8D1D-CB86690DF6AFQ30235581-AA8A7665-0F7B-4FAC-B1B1-294040C7D4BEQ30995889-477BADF0-402E-4DFB-AD80-061066CB078DQ33865593-26BB3247-7E7D-4F3A-8B41-483012133ED8Q33874790-B3485886-6BBD-44A7-A6C8-FB8E3C84713DQ34160082-6CF351F2-1D5D-46F9-904A-7A0F1D423B6DQ35945255-B33BB4B4-6999-48B0-9990-C41ADE061BD3Q36910636-234ABBE5-91B6-4F0F-8DAD-1918DAE0B5DBQ38191334-15989A2F-1193-43D2-A625-6823856E33BCQ38317338-54BE1F12-B55C-48C4-9027-DBCFF75F6478Q38323592-7F210799-B068-45B2-89C9-8F2738504B61Q38568813-F92C1F88-1E11-497D-AFBC-6A6FE1DD3BAFQ38687407-A2BE1E47-C9F6-44F6-ACBC-C72D1D162770Q38723611-BB6CF74C-790E-4BE0-921C-86032BCF72CCQ38902205-95AF45F9-BF78-4787-90D5-D8532DE584B9Q43032312-27038A16-54E5-4CE0-AC2A-3078439F47BDQ47109861-F7A0BD3E-8FE7-4E24-893D-82C398FBE8B9Q47736134-B90BB847-8FE9-4144-8938-DC6FD9AFE0E9Q51741798-8542A780-6682-497B-A7B8-DE020649586A
P2860
Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Comprehensive review: antitumo ...... plicated in treatment response
@en
type
label
Comprehensive review: antitumo ...... plicated in treatment response
@en
prefLabel
Comprehensive review: antitumo ...... plicated in treatment response
@en
P2860
P356
P1476
Comprehensive review: antitumo ...... plicated in treatment response
@en
P2093
Gary R Lichtenstein
P2860
P304
P356
10.1177/1756283X13479826
P577
2013-07-01T00:00:00Z